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ABSTRACT  
Background: Lower birth weight is associated with increased susceptibility to 
cardiometabolic diseases in adulthood, but the underlying molecular pathways are 
incompletely understood. We examined associations of birth weight with a comprehensive 
metabolic profile measured in adolescents and adults. 
Methods: High-throughput nuclear magnetic resonance metabolomics and biochemical 
assays were used to quantify 87 circulating metabolic measures in seven cohorts from 
Finland and the United Kingdom comprising altogether 18 288 individuals (mean age 26 
years, range 15–75). Metabolic associations with birth weight were assessed by linear 
regression models adjusted for sex, gestational age, and age at blood sampling. The 
metabolic associations with birth weight were compared to the corresponding associations 
with adult body mass index (BMI). 
Results: Lower birth weight adjusted for gestational age was adversely associated with 
cardiometabolic biomarkers, including lipoprotein subclasses, fatty acids, amino acids, and 
markers of inflammation and impaired liver function (P<0.0015 for 46 measures). 
Associations were consistent across cohorts with different ages at metabolic profiling, but 
the magnitudes were weak. The pattern of metabolic deviations associated with lower birth 
weight resembled the metabolic signature of higher adult BMI (R2=0.77) assessed at the 
same time as the metabolic profiling. The resemblance indicated that 1-kg lower birth 
weight is associated with similar metabolic aberrations as caused by 0.92-units higher BMI in 
adulthood. 
Conclusion: Lower birth weight adjusted for gestational age is associated with adverse 
biomarker aberrations across multiple metabolic pathways. Coherent metabolic signatures 
between lower birth weight and higher adult adiposity suggest that shared molecular 
pathways may potentially underpin the metabolic deviations. However, the magnitudes of 
metabolic associations with birth weight are modest in comparison to the effects of 
adiposity, implying that birth weight is only a weak indicator of the metabolic risk profile in 
adulthood.  
 
Key words: fetal programming, metabolic signatures, metabolomics, adiposity, fatty acids, 
amino acids.  
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KEY MESSAGES:  
• Lower birth weight adjusted for gestational age is adversely associated with a wide range 
of established and emerging circulating cardiometabolic biomarkers in adulthood, 
including lipoprotein subclasses and their lipids, fatty acid balance, amino acids, and 
markers of inflammation and liver function. 
• The metabolic associations are consistent across a wide age span from adolescence to 
retirement age, coherent for men and women, and broadly similar with and without 
adjustment for gestational age. 
• Despite statistical significance of the metabolic associations with birth weight, the 
magnitudes of individual metabolic aberrations are weak for the variation in birth weight 
observed in general population cohorts.  
• The overall metabolic association pattern with lower birth weight closely resembles the 
metabolic signature of higher adult adiposity. This may suggest that shared molecular 
pathways could underlie the fine-grained metabolic aberrations associated with both 
fetal growth and adiposity. 
• 1-kg lower birth weight (≈2 SD) is associated with similar adverse metabolic effects as 
caused by 0.92 higher BMI (≈0.25 SD) in adulthood. These findings indicate that birth 
weight, as a surrogate marker for fetal growth, appears to only have modest effects on 
the adult metabolic risk profile in general population settings.  
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INTRODUCTION 
Birth weight is a marker of fetal growth rate and lower birth weight has been associated with 
increased rates of ischemic heart disease, stroke, and type 2 diabetes in adulthood.1-4 These 
observations from multiple epidemiological studies have been interpreted according to the 
developmental-origins hypothesis, which proposes that fetal adaptive responses to 
suboptimal nutrition in utero may permanently alter the fetal organ structure and metabolic 
homeostasis, and hereby increase susceptibility to diseases that occur later in life.5,6 This 
appears especially if fetal undernutrition is accompanied with abundant postnatal 
nutrition.7,8 The developmental-origins hypothesis is supported by evidence from animal 
studies indicating that the foetus may adapt to an adverse intrauterine environment by 
slowing down growth and metabolism, which is turn has effects on adult organ size, 
structure and physiological function.6,9,10 This adaptive strategy appears to increase short-
term survival, but perhaps with adverse long-term consequences on health. Also human 
genetic evidence has linked fetal growth with adult metabolism and diabetes risk, yet the 
adverse influences of birth weight-lowering genes has been conflicting.11 However, despite 
the epidemiological evidence and animal models, the underlying molecular mechanisms 
linking impaired fetal growth to adult disease are poorly understood and the potential 
causality remains unclear.  
 
Life-long perturbations in causal metabolic risk factors induced via fetal response to a 
limiting intrauterine environment, e.g., elevated low-density lipoprotein (LDL) cholesterol, 
hypertension and type 2 diabetes, might represent pathways how impaired fetal growth 
could affect cardiometabolic risk in adulthood.2,3 Numerous studies have shown associations 
between lower birth weight and adverse levels of metabolic risk factors in adulthood; these 
include insulin resistance and impaired glucose tolerance,12-14, higher blood pressure15 and 
low-grade inflammation.16 Also adverse differences in cholesterol concentrations for lower 
birth weight have been reported in many studies across wide age ranges;15,17,18 however, 
meta-analyses indicate modest magnitudes of association (≈0.05 mmol/L higher total 
cholesterol per 1-kg lower birth weight).15,17 Controversy prevails regarding the associations 
of birth weight with other circulating lipids, such as LDL cholesterol and triglyceride levels, 
and the potential relevance of such modest lipid aberrations as mediators of the adult 
disease risk has been questioned.15  
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The molecular effects of impaired fetal growth involve multiple metabolic pathways which 
extend beyond routine risk markers;6 however, the wider influences on the systemic 
metabolic profile have not been assessed in large populations. Metabolomics is a powerful 
tool to study fine-grained molecular profiles and is therefore an attractive tool to study how 
birth weight is reflected on a comprehensive metabolic profile in adulthood. Nuclear 
magnetic resonance (NMR) metabolomics enables quantitative metabolic profiling of large 
blood sample collections.19 This methodology provides detailed lipoprotein subclass 
profiling, as well as quantification of fatty acids and small molecules that have recently been 
linked with the risk for cardiovascular disease and diabetes.20-24 These biomarkers could 
potentially serve as molecular intermediates between impaired intra-uterine growth and 
cardiometabolic risk. Studying the associations of birth weight with the detailed metabolic 
may therefore help to clarify the underlying mechanisms linking fetal growth with adult-
onset disease and eventually help to inform how the risk could be mediated.25 The metabolic 
profiling across multiple pathways simultaneously may further provide a more 
comprehensive view on the systemic effects of impaired fetal growth than would be 
obtained by examining individual biomarkers from a single molecular pathway. However, 
only few metabolomics studies on birth weight have been conducted to date. These studies 
have been limited to a very small number of individuals, have focused on preterm birth at 
very low birth weight, and primarily assessed associations with metabolites measured from 
umbilical cord blood.26-28 No study has previously used metabolomics to assess the role of 
birth weight on adult metabolic profiles in large general population settings.  
 
To characterize metabolic signatures of lower birth weight, we used serum NMR 
metabolomics of 18 288 individuals from seven cohorts, which together cover individuals 
from adolescence to the end of working age. We further compared how the metabolic 
association pattern with birth weight resembles the association pattern of adiposity in 
adulthood for the same extensive panel of metabolic measures. 
 
METHODS 
Study populations 
  6 (26) 
The study comprised six Finnish cohorts and one cohort from the United Kingdom (Table 1): 
the children part of the Avon Longitudinal Study of Parents and Children (ALSPAC; n=2874; 
metabolic profiles measured from blood samples drawn at age 17)29; the Northern Finland 
Birth Cohort (NFBC) 1986 (n=5579; age 16)30 and NFBC 1966 (n=5412; age 31)31, the 
Cardiovascular Risk in Young Finns Study (YFS; n=2273; age 24–48)32, the FinnTwin studies 
FT12 (n=767, age 21–25) and FT16 (n=495, age 23–30)33, and the Helsinki Birth Cohort Study 
(HBCS; n=890; age 62–75)8. Details of the cohorts related to the present study are described 
in the Supplementary Methods (available as Supplementary data at IJE online). Birth weight 
and gestational age were assessed by a midwife, birth medical records or antenatal care. 
Gestational age was defined as a categorical variable indicating completed weeks of 
gestation. Out of 19 622 eligible individuals with metabolic profiling data, 18 649 had 
complete data on birth weight, gestational age, and adult body mass index (BMI). BMI was 
measured in adolescence or adulthood at the same time as the blood sampling for metabolic 
profiling in all cohorts (henceforth denoted adult BMI). Women who were pregnant (n=115) 
and individuals on lipid-lowering medication (n=246) at the time of metabolic profiling were 
excluded, leaving 18 288 individuals for the present analysis. All study participants provided 
informed consent, and study protocols were approved by the local ethical committees. 
 
Lipid and metabolite quantification 
Fasting blood samples were collected as part of the clinical examinations in adolescence and 
in adulthood and stored as serum or EDTA plasma at -80°C for subsequent biomarker 
profiling as detailed in Supplementary Methods. Altogether 87 metabolic measures were 
analysed for the present study. A high-throughput NMR metabolomics platform was used for 
the quantification of 77 metabolic measures.19 This metabolomics platform provides 
simultaneous quantification of routine lipids, lipid concentrations of 14 lipoprotein 
subclasses and major subfractions, and further quantifies abundant fatty acids, amino acids, 
ketone bodies and gluconeogenesis-related metabolites in absolute concentration units 
(Table S1). The metabolic profiling therefore includes both routine risk markers and novel 
metabolic biomarkers that have not previously been examined in relation to birth weight. 
The NMR metabolomics platform has been extensively applied for biomarker profiling in 
epidemiological studies20,21,23-25,34,35 and details of the experimentation have been described 
elsewhere.19,36 In addition to the NMR metabolomics measures, 10 metabolic markers 
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related to inflammation, liver function and hormone balance, assayed in two or more of the 
cohorts, were analysed as part of the comprehensive metabolic profile (Supplementary 
Methods).25 Mean (SD) concentrations of the metabolic measures in each cohort are listed 
in Table S2. 
 
Statistical analyses 
Metabolic measures with skewed distributions (skewness>2) were normalized by log-
transformation prior to analyses. Linear regression models for each metabolite were tested 
with birth weight as the explanatory variable and the metabolite concentration as an 
outcome. Associations were adjusted for sex, age at blood sampling, and gestational age. 
Adjusting birth weight for gestational age broadly means that the birth weight variable may 
be interpreted in terms of growth rate. Results were analysed separately for the seven 
cohorts and combined using fixed effect inverse-variance weighted meta-analysis after 
verifying the consistency across the seven cohorts. Association magnitudes are quantified in 
SD-units of metabolite concentration per 1-kg lower birth weight (≈2 SD). Due to the 
correlated nature of the metabolic measures, >95% of the variation in the 87 measures was 
explained by at most 34 principal components in each cohort. Multiple testing correction 
therefore accounted for 34 independent tests using the Bonferroni method, resulting in 
P<0.0015 denoted statistically significant.  
 
The pattern of metabolic associations with birth weight was compared to the corresponding 
cross-sectional metabolic associations with adult BMI, using the same approach as used for 
birth weight but without adjustment for gestational age. The overall correspondence 
between the metabolic association patterns of birth weight and adult BMI were summarized 
using the R2 and slope of the linear fit.25,35 
 
To examine whether there was evidence for curvilinear associations we assessed the shape 
of the associations using local quadratic regression fitting, with each smoothing function 
evaluated at 25 points through the range of birth weight. Absolute concentrations of each 
metabolic measure were first regressed for age and sex, and the resulting residuals were 
pooled and rescaled to absolute units prior to fitting.35 
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RESULTS 
The study comprised 18 288 adolescents and adults from five general population cohorts 
and two twin cohorts from Finland and the UK (Table 1). Distributions of birth weight for 
each cohort are illustrated in Figure S1. Only 1% of the singleton participants had a birth 
weight of <2 kg. Birth weight was correlated with adult BMI (r=0.09) in a broadly linear 
manner for most of the cohorts (Figure S2).  
 
Lipoprotein measures 
Associations of birth weight with 43 lipoprotein measures are shown in Figure 1. In the 
meta-analysis, birth weight was robustly associated with numerous lipoprotein measures 
(P<0.0015 for 25 measures). While the associations of routine cholesterol measures were of 
modest magnitudes, somewhat stronger associations were observed for many of the more 
detailed lipid measures. Lower birth weight was associated with higher circulating 
apolipoprotein B (apoB) and total lipid concentrations in the apoB-carrying particles (very-
low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL) and LDL). The 
strongest associations with lipoprotein subclasses were observed for lipids in medium and 
small VLDL particles. Associations were weaker for lipids in IDL and LDL particles, albeit with 
stronger association magnitude for lipids in small LDL. Associations were more 
heterogeneous for lipids in high-density lipoprotein (HDL) particles: lower birth weight was 
associated with lower concentrations of circulating lipids in large HDL particles, but with 
higher concentrations of those in small HDL (i.e., in the same direction as for the apoB-
carrying lipoproteins). Birth weight was also robustly associated with the average size of the 
lipoprotein particles, with increased VLDL size and decreased LDL and HDL size related to 
lower birth weight. Within a given lipoprotein class, associations with birth weight tended to 
be stronger for triglycerides than for cholesterol and phospholipid levels.  
 
To enable comparison of birth weight associations across the metabolic measures, all 
association magnitudes are scaled to SD-units of metabolite concentration per 1-kg lower 
birth weight. The corresponding associations in absolute units, e.g., mmol/L per kg, are listed 
in Table S1. For instance, total triglyceride concentration was among the measures most 
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strongly associated with birth weight, with each 1-kg lower birth weight being associated 
with 0.04 mmol/L higher serum triglyceride concentration. 
 
Fatty acids 
Associations of birth weight with 16 fatty acid measures are shown in Figure 2. Lower birth 
weight was robustly associated with higher absolute concentration of all fatty acids assayed 
except docosahexaenoic acid. The strongest associations were observed for total, saturated 
and monounsaturated fatty acids (MUFA), which displayed association magnitudes 
comparable to that of apoB. Somewhat weaker associations were observed for omega-6 and 
omega-3 fatty acids. For the fatty acid ratios, the proportion of saturated fatty acids and 
MUFAs tended to be higher among individuals with lower birth weight, whereas the 
proportion of omega-6 fatty acids were lower.  
 
Non-lipid metabolic measures 
Associations of birth weight with 28 non-lipid metabolites and other metabolic measures are 
shown in Figure 3. Lower birth weight was associated with higher concentrations of alanine, 
branched-chain and aromatic amino acids. These amino acid associations with birth weight 
were of comparable magnitude to that of apoB. Lower birth weight was not robustly 
associated with glucose, while other gluconeogenesis-related metabolites displayed stronger 
associations. Lower birth weight was also robustly associated with higher levels of insulin 
and certain markers for low-grade inflammation and impaired liver function.  
 
Resemblance between metabolic signatures of birth weight and adult BMI 
The overall pattern of metabolic associations with lower birth weight was reminiscent of the 
metabolic association pattern with adiposity assessed at the same time as the blood 
sampling (Figure S3).25,37,38 We therefore compared the metabolic associations of birth 
weight to the corresponding metabolic associations of adult BMI (Figure 4). The resemblance 
between the metabolic association patterns was high, as indicated by the goodness-of-fit 
being R2=0.77. The slope denotes that 1-kg lower birth weight is associated with similar 
magnitudes of metabolic aberrations as those linked with 0.92 higher adult BMI-units 
(kg/m2). A similar resemblance with the association pattern with lower birth weight was 
observed for higher adult weight (R2=0.75), indicating that metabolic associations with 1-kg 
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lower birth weight were similar to those linked with 3.1 kg higher adult weight. In contrast, 
the pattern of metabolic associations with adult height was considerably different 
(Figure S4; R2=0.17).  
 
Consistency and sensitivity analyses 
Despite differences in age at blood sampling, the associations of birth weight with the 
metabolic measures were generally consistent across the seven cohorts and displayed little 
evidence of heterogeneity (Figure S5). The results were also generally similar and statistically 
consistent for men and women (Figure S6). The association magnitudes were also similar (on 
average 5% weaker) if omitting participants within the lowest percentile (birth weight <2.0 
kg) and highest percentile (birth weight >4.7 kg). The metabolic associations were slightly 
weaker (on average 8%) if omitting gestational age as a covariate (Figure S7). However, 
gestational age modelled as the primary exposure was essentially not associated with 
metabolic aberrations in adulthood (Figure S7), indicating that growth rate rather than 
length of gestation is important in relation to metabolic deviations.39 The metabolic 
associations with birth weight followed a similar pattern if adjusting for adult BMI (assessed 
at the same time as the blood sampling), however this adjustment increased the magnitude 
of association by 58% on average (Figure S8). The continuous shapes of the metabolic 
associations with birth weight are illustrated in Figure S9. Most associations were 
approximately linear across the birth weight distribution, justifying the use of linear 
regression modelling. 
 
DISCUSSION 
In this meta-analysis of 18 288 individuals, lower birth weight (adjusted for gestational age) 
was adversely associated with numerous blood-based biomarkers across the comprehensive 
metabolic profile, including lipoprotein subclass measures, fatty acid composition, amino 
acids as well as markers of inflammation and liver function. The metabolic associations were 
all in a direction of higher risk for diabetes and cardiovascular disease, both for established 
risk factors and emerging biomarkers. The associations were coherent across seven cohorts 
with a wide age range at metabolic profiling, from adolescence through adulthood, 
suggesting that these metabolic aberrations are lifelong. These findings are coherent with 
the developmental origins hypothesis, proposing long-term alterations in metabolic 
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homeostasis.6 However, although many of the associations were statistically robust in this 
large study sample, the small association magnitudes indicate that the influences of birth 
weight on systemic metabolism are modest. 
 
The wide palette of the metabolic deviations associated with lower birth weight have 
previously been linked with increased risk for cardiometabolic diseases.19-24 Among the 
lipoprotein measures adversely associated with lower birth weight were both cholesterol-rich 
LDL particles and triglyceride-rich VLDL particles. Genetic evidence suggests that both these 
types of apoB-carrying lipoproteins are causally related to ischemic heart disease.40 
Associations with routine cholesterol measures were modest, in line with prior meta-analyses 
that have questioned the relevance of associations between birth weight and circulating 
lipids.15,17,41 Although the lipoprotein subclass profiling indicated somewhat stronger and 
statistically robust associations with several more detailed lipid measures, the associations 
were nevertheless in line with the overall weak metabolic aberrations. 
 
Increased circulating levels of omega-3 fatty acids have been associated with lower risk for 
future cardiovascular disease events.20 Whilst dietary supplementation of omega-3 fatty acids 
has been suggested as intervention for people born with impaired fetal growth,42 the serum 
levels of omega-3 have not been robustly linked with birth weight. Here, the association of 
birth weight was flat for the proportion of omega-3 fatty acids relative to total fatty acids. 
However, the proportion of omega-6 fatty acids — also inversely associated with the risk for 
cardiovascular disease20 and diabetes23— was decreased in relation with lower birth weight. 
The small magnitudes of the fatty acid perturbations are unlikely to substantially mediate the 
associations between lower birth weight and increased susceptibility to cardiometabolic 
diseases.  
 
Recent metabolomics studies have shown that amino acids and many other circulating 
metabolites are predictive of the risk for diabetes, cardiovascular disease, and all-cause 
mortality.20-22,24,43 For instance, elevated circulating levels of branched-chain and aromatic 
amino acids have been robustly associated with insulin resistance, hyperglycaemia and 
diabetes risk in a number of studies.22,24,43 Aromatic amino acids have also been shown to be 
predictors of cardiovascular event risk, even more strongly than LDL cholesterol.20 All these 
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amino acids were found to be elevated for lower birth weight, i.e., in the direction consistent 
with higher metabolic risk. Lower birth weight was also related to higher concentrations of 
markers for impaired liver function, insulin resistance and chronic inflammation. These 
metabolic markers are also predictive for the risk of a broad span of chronic diseases and all-
cause mortality.21,44,45 Importantly, while the individual biomarker associations with birth 
weight are all modest, the combined metabolic aberrations may in concert potentially 
contribute to mediate the relation between birth weight and cardiometabolic disease risk. 
 
Elevated BMI has recently been shown to have a causal metabolic signature across 
biomarkers from multiple pathways.25 This metabolic signature of adiposity is highly 
reminiscent of the pattern of metabolic associations here linked with lower birth weight. The 
similarity in the detailed association patterns illustrates how comprehensive metabolic 
profiling may help to pinpoint molecular connections between the metabolic effects of 
different risk factors. The resemblance between the metabolic signatures allows to 
summarize the metabolic aberrations linked with birth weight in relation to the effects of 
adiposity: 1-kg lower birth weight in the general population is associated with similar 
metabolic deviations as those caused by 0.92 kg/m2 higher BMI in adulthood. The 
consistency with the metabolic association pattern for birth weight was driven by adult 
weight rather than height, suggesting that the underlying mechanisms are not primarily 
related to stature. A 1-kg difference in birth weight is substantial, corresponding to almost 
2 SDs. A similar variance in adulthood BMI (i.e., a 2 SD greater adult BMI) is associated with 
8-fold stronger metabolic deviations, indicating much more pronounced metabolic 
perturbations associated with higher adult adiposity than those linked with lower birth 
weight.  
 
The prominent correspondence between the metabolic signatures of lower birth weight and 
elevated BMI leads us to speculate that impaired fetal growth and adiposity may have 
shared molecular pathways underlying the fine-grained metabolic aberrations. As a corollary 
of this hypothesis, we anticipate that the causal effects of BMI on also other molecular 
markers46 and physiological factors can be used to predict the anticipated association of 
birth weight with these same outcomes. For instance, genetic evidence indicates that the 
lifelong causal effect of BMI on systolic blood pressure is 0.9 mmHg per higher BMI-unit;25,47 
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based on the above hypothesis we extrapolate that the association of birth weight with 
systolic blood pressure would be 0.9×0.92 ≈ 0.8 mmHg per 1-kg lower birth weight. This is 
broadly consistent with the association observed in meta-analysis.37,38 Since our results 
indicate that the metabolic perturbations associated with birth weight are present across 
the lifecourse, it is important that such extrapolation of birth weight associations with other 
risk markers is based on lifelong effects of BMI, e.g., from genetic estimates. Based in this 
principle, it is also possible to estimate the association of birth weight with cardiometabolic 
disease risk by comparison to the risk effects caused by BMI. Accordingly, 0.92 BMI-units is 
causally associated with ≈10% higher risk for ischemic heart disease,48,49 which is consistent 
with meta-analysis results on the risk magnitude for ischemic heart disease per 1-kg lower 
birth weight.2 Similarly, 0.92 BMI-units is causally associated with 24–33% higher risk for 
type 2 diabetes47,50, which again is consistent with meta-analysis estimates of the diabetes 
risk per 1-kg lower birth weight.3 These results seem to suggest that the comprehensive 
metabolic effects corresponding to as little as 0.92 BMI-units, affecting over the lifecourse, 
may be sufficient to explain the association of birth weight with cardiometabolic disease risk 
in adulthood. However, we acknowledge that the specific mechanisms linking birth weight 
and adiposity to cardiometabolic outcomes may be different despite the shared metabolic 
signatures. 
 
It is of note that although birth weight was ≈700 grams lower in the twin cohorts than in 
singletons, the metabolite concentrations and the pattern of metabolic associations with 
birth weight were generally similar to the other cohorts (Table S2 and Figure S5). This is 
consistent with no difference in diabetes prevalence or overall mortality among twin 
individuals compared to singletons51,52, supporting our conclusion that lower birth weight 
per se has a minor long-term impact on the systemic metabolic risk profile. However, direct 
comparison of potential small metabolic differences due to lower birth weight in twins is not 
feasible in this study due to confounding differences in cohort characteristics as well as 
variations between cohorts in pre-analytic sample handling, storage duration and type of 
blood specimen (serum vs. plasma). The metabolic associations with birth weight were 
stronger (on average 58%) if adjusting for adult BMI, in line with prior studies on metabolic 
risk factors,3,15,17,37 suggesting that birth weight in relation to current weight is more relevant 
for adulthood metabolic aberrations than birth weight alone. The adjustment for adult BMI 
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has been considered inappropriate due to the correlation of BMI with both birth weight and 
metabolite levels.37,53 However, the BMI-adjusted results may be interpreted as a measure 
of change in size between birth and adulthood,53,54 and the stronger metabolic associations 
observed here accordingly indicates a contributing role of postnatal growth. Further studies 
on the comprehensive metabolic effects of growth in infancy may clarify the role of 
compensatory growth and other proposed interactions with birth weight on the metabolic 
profile in adulthood.8,54 
 
Strengths of this study include the large sample size, comprising seven cohorts with 
quantitative metabolomics data. Birth weight was obtained from birth medical records for 
88% of the study population, which minimizes bias from self-reporting, and data on 
gestational age allowed accounting for lower birth weight caused by prematurity. The 
broadly coherent results across cohorts of a wide age range provided a view to the life-
course effects of birth weight. However, the general population nature of the cohorts 
analysed prevents us from making conclusions regarding the specific metabolic effects of 
infants born preterm, or those with severe fetal growth restriction.28 Birth weight has 
limitations as a marker of impaired fetal growth, however it is the surrogate most widely 
reported in large population cohorts, and it has a high correlation with other markers of size 
at birth.17 We acknowledge that we cannot assume that impaired fetal growth is causal for 
the adulthood metabolic aberrations observed. For example, genetic analyses support a 
causal role for maternal smoking in pregnancy and higher blood pressure resulting on lower 
infant birth weight, which could potentially contribute to explain the weak inverse 
associations with metabolic risk markers observed here.55,56 Given the predominantly young 
age of the study participants we were not able to test whether the metabolic aberrations 
related to birth weight could mediate the relationship to cardiometabolic disease outcomes. 
Other metabolomics technologies may eventually provide further insights into the intricate 
metabolic effects of fetal growth, however the present study demonstrates that large 
sample size is required to robustly assess the weak associations. Finally, it is important to 
recognize that information on antenatal nutrition and other factors that might underlie the 
relationships of birth weight with metabolic outcomes might highlight associations of a 
larger magnitude or potentially greater importance than suggested by our results. 
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In conclusion, comprehensive metabolic profiling of large cohorts identified associations 
between lower birth weight (adjusted for gestational age) and adverse circulating levels of a 
wide panel of circulating cardiometabolic risk markers in adulthood. The overall metabolic 
signature of lower birth weight closely resembled the metabolic effects of higher BMI, 
suggesting that shared molecular pathways may underpin the perturbed metabolic profile 
related to both fetal growth and adiposity. Nevertheless, the aberrations were of modest 
magnitude, with similar metabolic perturbations related to 1-kg lower birth weight as those 
caused by lifelong effects of ≈3 kg higher body weight in adulthood. These results indicate 
that birth weight is only a weak indicator of the metabolic risk profile in adulthood.  
 
 
  16 (26) 
Supplementary Data (available at IJE online) 
Supplementary Methods: Study populations.  
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Figure S5. Metabolic associations with birth weight in each cohort. 
Figure S6. Metabolic associations with birth weight for men and women. 
Figure S7. Metabolic associations with birth weight without adjustment for gestational age and 
gestational age as predictor of adulthood metabolic aberrations. 
Figure S8. Metabolic associations with birth weight adjusted for adult BMI. 
Figure S9. Curvilinear shapes of metabolic associations with birth weight. 
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Table 1. Characteristics of the seven cohorts. 
Characteristics NFBC 1986 
ALSPAC 
Children 
Finn-Twin 
FT12 
Finn-Twin 
FT16 
NFBC 1966 
Young 
Finns 
Study 
Helsinki 
Birth 
Cohort 
Study 
Number of 
individuals 
5579 2874 767 495 5412 2273 890 
Men [%] 50.4 48.4 41.2 51.1 49.9 44.7 43.9 
Age at blood 
sampling [years] 
16.1 (0.4) 17.8 (0.4) 22.4 (0.6) 26.2 (1.3) 31.2 (0.4) 39.2 (6.1) 66.3 (2.9) 
Birth weight [g] 3562 (541) 3426 (546) 2703 (507) 2673 (495) 3498 (523) 3508 (543) 3432 (470) 
Gestational age 
[week] 
39.4 (1.8) 39.4 (1.6) 36.9 (2.2) 36.9 (2.5) 40.0 (1.9) 38.6 (1.2) 40.0 (1.5) 
Adult body mass 
index [kg/m2] 
21.2 (3.4) 23.0 (3.9) 23.3 (3.9) 23.8 (4.0) 25.6 (4.1) 26.3 (4.9) 27.0 (4.1) 
Systolic blood 
pressure [mm 
Hg] 
116 (13) 115 (10) – – 125 (13) 119 (14) 143 (19) 
Total-C [mmol/L] 4.3 (0.8) 3.8 (0.7) 4.7 (0.9) 5.0 (0.9) 5.0 (1.0) 5.1 (0.9) 6.1 (1.0) 
HDL-C [mmol/L] 1.4 (0.3) 1.4 (0.2) 1.8 (0.4) 1.8 (0.4) 1.5 (0.4) 1.3 (0.3) 1.7 (0.4) 
Triglycerides 
[mmol/L] 
0.7 
[0.6-1.0] 
0.8 
[0.7-1.0] 
0.9 
[0.7-1.2] 
1.2 
[0.9-1.62] 
1.0 
[0.7-1.4] 
1.1 
[0.8-1.5] 
1.2 
[0.9-1.7] 
Glucose 
[mmol/L] 
5.2 
[4.9-5.4] 
5.0 
[4.7-5.3] 
4.6 
[4.3-4.8] 
4.7 
[4.3-5.2] 
5.0 
[4.7-5.3] 
5.3 
[4.9-5.6] 
5.5 
[5.1-5.8] 
Insulin [IU/L] 
9.6 
[7.4-12.3] 
6.8 
[4.9-9.3] 
– – 
7.5 
[6.2-9.4] 
7.3 
[4.4-11.2] 
7.4 
[5.2-11.2] 
Values are mean (SD) and median [interquartile range] for normally distributed and 
positively skewed variables, respectively. 
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Figure 1. Birth weight associations with adult concentrations of lipoprotein lipids. The 
associations were adjusted for sex, gestational age, and age at blood sampling, and meta-
analysed for 18 288 individuals from 7 cohorts. Association magnitudes are 1-SD lipid 
concentration per 1-kg lower birth weight. Error bars denote 95% confidence intervals. Filled 
diamonds indicate P<0.0015. Association magnitudes in absolute concentration units and 
P-values are listed in Table S1. Results for individual cohorts are shown in Figure S5. 
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Figure 2. Birth weight associations with adult fatty acid levels. The associations were 
adjusted for sex, gestational age, and age at blood sampling, and meta-analysed for 18 288 
individuals from 7 cohorts. Association magnitudes are in units of 1-SD fatty acid measure 
per 1-kg lower birth weight. Fatty acid ratios are relative to the total fatty acid 
concentration. Error bars denote 95% confidence intervals. Filled diamonds indicate 
P<0.0015. Results for individual cohorts are shown in Figure S5. 
MUFA: mono-unsaturated fatty acids, PUFA: poly-unsaturated fatty acids, DHA: 
docosahexaenoic acid.  
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Figure 3. Birth weight associations with adult metabolite and hormonal concentrations. 
The associations were adjusted for sex, gestational age, and age at blood sampling, and 
meta-analysed for 18 288 individuals from 7 cohorts. Association magnitudes are in units of 
1-SD metabolite concentration per 1-kg lower birth weight. Error bars denote 95% 
confidence intervals. Filled diamonds indicate P<0.0015. Results for individual cohorts are 
shown in Figure S5. 
GlycA: Glycoprotein acetyls, SHBG: sex-hormone binding globulin.  
 
  26 (26) 
 
Figure 4. Resemblance between metabolic association patterns related to lower birth weight 
and higher adulthood BMI (assessed at the same time as blood sampling for metabolic 
profiling). The metabolic associations were assessed for the same 18 288 individuals. The red 
dashed line denotes the linear fit between metabolic associations with lower birth weight 
and higher BMI. The slope indicates that 1-kg lower birth weight is on average associated 
with similar metabolic deviations as those linked with 0.92 kg/m2 higher BMI in adulthood. 
 
